SPA
RCUS icon

Sherbrooke Park Advisers’s Arcus Biosciences RCUS Stock Holding History

Sherbrooke Park Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,767
Closed -$301K – 1198
2024
Q2 		$301K Buy
+19,767
New +$319K 0.05% 626

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sherbrooke Park Advisers's RCUS Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 19,767 shares — an estimated $301K sold.

Sherbrooke Park Advisers first reported a position in RCUS in Q2 2024 and held it in 1 quarter. The position peaked at $301K in Q2 2024. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 19,767 Arcus Biosciences shares in Q3 2024, an estimated $301K.
  • Sherbrooke Park Advisers first reported a position in Arcus Biosciences in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Arcus Biosciences position peaked at $301K in Q2 2024.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.